The
abnormally expressed peptidases in human tissues are associated
with many kinds of cancers. Monitoring of endogenous peptidase activity
could allow us for pathophysiology elucidation and early clinical
diagnosis. Herein, we developed a general strategy for bioluminescence
(BL) sensing of peptidase activity in vivo based on tumor-targeting
probiotics. The probiotic that harbored a luciferase-encoding plasmid
was used to target and colonize tumor and provide luciferase for BL
imaging. The peptide-based probes Lc and GPc were applied to track
leucine aminopeptidase (LAP) and dipeptidyl peptidase IV (DPPIV) activity,
respectively, by simply adding l-leucine and Gly-Pro dipeptides
at the N-terminus of d-cysteine, which were specifically
controlled by peptidase cleavage and released free d-cysteine
to conduct a subsequent click condensation reaction with 2-cyano-6-hydroxybenzothiazole
(HCBT) to produce firefly luciferin in situ, giving rise to a strong
BL signal. Neither gene modification of cells of interest nor complicated
synthesis was required in this BL system. Encouraged by these advantages,
we successfully used our probes to monitor LAP and DPPIV activities
in vitro and in vivo, respectively. A good linearity between BL and
peptidase was obtained in the concentration range of 2.5–40.0
mU/mL with a limit of detection (LOD) of 1.1 mU/mL (55 ng/mL) for
LAP and 2.0–40.0 mU/mL with a LOD of 0.78 mU/mL (1.15 ng/mL)
for DPPIV, respectively. Additionally, approximately 5-fold (LAP)
and 10-fold (DPPIV) differences in the BL signal before and after
treatment with a specific inhibitor were also obtained for in vivo
BL imaging. All these results reflected the potential application
value of our probes in BL sensing of peptidase activity. We envision
that our strategy may be a useful approach for monitoring a wide range
of peptidases in tumors, especially in primary tumors.